Teste de caminhada de seis minutos: uma ferramenta valiosa na avaliação do comprometimento pulmonar

Morales-Blanhir, Jaime Eduardo; Palafox, Damián; Romero, María de Jesús R Rosas; Castro, Mauro Marcos García; Villegas, Alejandro Londoño; Zamboni, Mauro

doi:10.1590/s1806-37132011000100016

Cited by 85 publications

(83 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Endurance testing in MPS VI patients as measured by the 6MWT provides an indication of cardiopulmonary health, endurance, mobility and extent of morbidity [Morales-Blanhir et al, 2011]. In the Resurvey Study, the patients who completed the 6MWT walked a mean of 65.7 m ( P <.0001) more at follow-up.…”

Section: Discussionmentioning

confidence: 99%

Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux–Lamy syndrome)—10‐year follow‐up of patients who previously participated in an MPS VI survey study

Giugliani

Lampe

Guffon

et al. 2014

American J of Med Genetics Pt A

123

View full text Add to dashboard Cite

Mucopolysaccharidosis VI (MPS VI) is a clinically heterogeneous and progressive disorder with multiorgan manifestations caused by deficient N-acetlylgalactosamine-4-sulfatase activity. A cross-sectional Survey Study in individuals (n=121) affected with MPS VI was conducted between 2001–2002 to establish demographics, urinary glycosaminoglycan (GAG) levels, and clinical progression of disease. We conducted a Resurvey Study (ClinicalTrials.gov: NCT01387854) to obtain 10-year follow-up data, including medical histories and clinical assessments (n=59), and survival status over 12-years (n=117). Patients received a mean (SD) of 6.8 (2.2) years of galsulfase ERT between baseline (Survey Study) and follow-up. ERT patients increased in height by 20.4 cm in the 4–7 year-old baseline age group and by 16.8 cm in the 8–12 year-old baseline age group. ERT patients <13 years old demonstrated improvement in forced vital capacity (FVC) by 68% and forced expiratory volume in 1 second (FEV1) by 55%, and those ≥13 years old increased FVC by 12.8% and maintained FEV1. Patients with >200 µg/mg baseline uGAG levels increased FVC by 48% in the <13 year-old and by 15% in the ≥13 year-old baseline age group. ERT patients who completed the 6-minute walk test demonstrated a mean (SD) increase of 65.7 (100.6) m. Cardiac outcomes did not significantly improve or worsen. Observed mortality rate among naïve patients was 50% (7/14) and 16.5% (17/103) in the ERT group (unadjusted hazard ratio, 0.24; 95% CI, 0.10 to 0.59). Long-term galsulfase ERT was associated with improvements in pulmonary functions and endurance, stabilized cardiac function and increased survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux–Lamy syndrome)—10‐year follow‐up of patients who previously participated in an MPS VI survey study

Giugliani

Lampe

Guffon

et al. 2014

American J of Med Genetics Pt A

123

View full text Add to dashboard Cite

show abstract

“…( 1 , 2 ) End-exercise PaO 2 decreases after maximal exercise, and submaximal steady-state exercise was found to be an important measure of disease severity in interstitial pulmonary fibrosis. ( 3 , 4 ) Lama et al demonstrated that patients with usual interstitial pneumonia who developed oxygen desaturation during and after a six-minute walk test (6MWT)–a ≥ 4% decrease in oxygen saturation from baseline (∆sat ≥ 4%)–were more than four times more likely to die during follow-up.…”

Section: Introductionmentioning

confidence: 99%

“…( 1 , 2 ) A PaO 2 ao final do exercício diminui após o exercício máximo, e o exercício de estado estacionário submáximo mostrou-se uma importante medida da gravidade da doença na fibrose pulmonar intersticial. ( 3 , 4 ) Lama et al demonstraram que pacientes com pneumonia intersticial usual que apresentaram dessaturação de oxigênio durante e após um teste de caminhada de seis minutos (TC6) – uma diminuição ≥ 4% da saturação de oxigênio em relação à saturação basal (Î"sat ≥ 4%) – eram mais de quatro vezes mais propensos a morrer durante o seguimento.…”

Section: Introductionunclassified

Oxygen desaturation in healthy subjects undergoing the incremental shuttle walk test

Seixas

Pereira

et al. 2013

J. bras. pneumol.

View full text Add to dashboard Cite

OBJECTIVE: To determine the probability of oxygen desaturation in healthy individuals undergoing the incremental shuttle walk test (ISWT). METHODS: We enrolled 83 healthy subjects: 55 males (including 1 smoker) and 28 females. We determined pre-ISWT FEV1, FEV6, HR and SpO2, as well as post-ISWT HR and SpO2. RESULTS: Mean values overall were as follows: age, 35.05 ± 12.53 years; body mass index, 24.30 ± 3.47 kg/m2; resting HR, 75.12 ± 12.48 bpm; resting SpO2, 97.96 ± 1.02%; FEV1, 3.75 ± 0.81 L; FEV6, 4.45 ± 0.87 L; FEV1/FEV6 ratio, 0.83 ± 0.08 (no restriction or obstruction); incremental shuttle walk distance, 958.30 ± 146.32 m; post-ISWT HR, 162.41 ± 18.24 bpm; and post-ISWT SpO2, 96.27 ± 2.21%. In 11 subjects, post-ISWT SpO2 was higher than was pre-ISWT SpO2. In 17 subjects, there was a 4% decrease in SpO2 after the ISWT. There were no statistically significant differences between the groups with and without post-ISWT oxygen desaturation in terms of age, gender, FEV1, FEV6, FEV1/FEV6, pre-ISWT SpO2, incremental shuttle walk distance, HR, or percentage of maximal HR. In the individuals with post-ISWT oxygen desaturation, the body mass index was higher (p = 0.01) and post-ISWT SpO2 was lower (p = 0.0001). CONCLUSIONS: Healthy individuals can present oxygen desaturation after the ISWT. Using the ISWT to predict subtle respiratory abnormalities can be misleading. In healthy subjects, oxygen desaturation is common after the ISWT, as it is during any intense physical activity.

show abstract

“…Even as a submaximal exercise test, 6MWT assists in making the most appropriate therapeutic measures [24]. Moreover, it presents itself as a promising tool in the field of medical research, so Tx experts should also be aware of its both pre-and postoperatively advantages [29].…”

Section: Discussionmentioning

confidence: 99%

Clinical and functional capacity of patients with dilated cardiomyopathy after four years of transplantation

Mont’Alverne¹,

Galdino²,

Pinheiro³

et al. 2012

Revista Brasileira De Cirurgia Cardiovascular

View full text Add to dashboard Cite

Objective: To evaluate patient with cardiomyopathy's progress after cardiac transplant, by analyzing his survival, complications and cardiovascular responses after nearly four years of surgery.Methods: The survey was conducted from February to May 2011, with patients undergoing cardiac transplantation at Dr. Carlos Alberto Studart Gomes Hospital -Messejana Hospital (HDM). The sample consisted of all transplanted patients in 2007 in this hospital. Initially an evaluation form developed by the researchers, which was based on collected data from patients' medical records, was applied, about trans and postoperative period. After collecting these informations, patients underwent the six-minute walk test (6WT). The marks found in walking distance were compared with reference marks expected for this population by using Enright and Sherrill's equation.Results: From all the 24 patients who underwent cardiac transplantation in HDM in 2007, 14 were evaluated and 10 were excluded. Regarding the complications, in the transoperatory period, the most evident was the right ventricular dysfunction (64.3%) and tachycardia (64.3%) was more evident on the postoperative period. Analyzing the 6WT it was observed a decrease of 11.6% in walking distance when compared with the estimated distance (486 ± 55 m, 550 ± 59 m, respectively).Conclusion: Survival of heart transplant patients was equivalent to about 70%. The results of this study before the 6WT showed that patients' cardiovascular responses are below the estimated, nevertheless within the normal range established.Descriptors: Cardiomyopathies. Cardiomyopathy, dilated. Heart transplantation. Walking. 563Rev Bras Cir Cardiovasc 2012;27(4) :562-9 Mont'Alverne DGB, et al. -Clinical and functional capacity of patients with dilated cardiomyopathy after four years

show abstract

Teste de caminhada de seis minutos: uma ferramenta valiosa na avaliação do comprometimento pulmonar

Cited by 85 publications

References 46 publications

Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux–Lamy syndrome)—10‐year follow‐up of patients who previously participated in an MPS VI survey study

Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux–Lamy syndrome)—10‐year follow‐up of patients who previously participated in an MPS VI survey study

Oxygen desaturation in healthy subjects undergoing the incremental shuttle walk test

Clinical and functional capacity of patients with dilated cardiomyopathy after four years of transplantation

Contact Info

Product

Resources

About